BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
March 31, 2021 23:21 ET
|
BeyondSpring, Inc.
– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone ...
BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
March 11, 2021 16:01 ET
|
BeyondSpring, Inc.
Webinar on Thursday, March 18th @ 10:00 a.m. ET NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical...
UPDATE -- BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
December 29, 2020 09:19 ET
|
BeyondSpring, Inc.
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
December 29, 2020 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
December 17, 2020 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
December 10, 2020 08:00 ET
|
BeyondSpring, Inc.
- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone - The plinabulin + pegfilgrastim combination...
BeyondSpring to Present at Two Upcoming Scientific Conferences in December
November 24, 2020 20:59 ET
|
BeyondSpring, Inc.
BeyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast Cancer Symposium NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) --...
BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
November 23, 2020 16:01 ET
|
BeyondSpring, Inc.
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology...
BeyondSpring Announces Pricing of Ordinary Shares
November 19, 2020 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
November 17, 2020 16:01 ET
|
BeyondSpring, Inc.
NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...